로딩 중...
52주 최고가 대비 73.8% 위치
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2022년 | 2023년 | 2024년 | 2025년 | 2026년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $276.71B | $308.95B | $359.05B | $403.43B |
| 영업이익 | - | $4.58B | $4.17B | $4.82B | $6.45B |
| 당기순이익 | - | $3.56B | $3.00B | $3.29B | $4.76B |
| 잉여현금흐름 (FCF) | - | $4.60B | $3.63B | $5.23B | $5.41B |
| 수익성 비율 | |||||
| 영업이익률 | - | 1.7% | 1.4% | 1.3% | 1.6% |
| 순이익률 | - | 1.3% | 1.0% | 0.9% | 1.2% |
| ROE (자기자본이익률) | - | -191.7% | -152.3% | -158.9% | -219.2% |
| ROA (자산이익률) | - | 5.7% | 4.5% | 4.4% | 5.8% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 11.7% | 16.2% | 12.4% |
| EPS 성장률 (YoY) | - | - | -10.5% | 14.9% | 49.2% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 14.3x | 23.8x | 27.6x | 21.2x |
| PBR (주가순자산배수) | - | - | - | - | - |
| PSR (주가매출배수) | - | 0.2x | 0.2x | 0.2x | 0.2x |
| FCF Yield | - | 10.7% | 5.7% | 6.1% | 5.5% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | -3.93 | -3.75 | -3.56 | -3.97 |
| 유동비율 | - | 0.92 | 0.92 | 0.90 | 0.85 |
MOLINA HEALTHCARE INC
$179.86
$9.4B